All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

Positive interim results announced for TRPH-222 in patients with NHL

May 21, 2020
Share:

On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222 (NCT03682796). This trial investigated the efficacy and safety of the next-generation antibody-drug conjugate, TRPH-222, in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma (non-Hodgkin lymphoma; NHL).  The primary aim was to determine the maximum tolerated dose of TRPH-222; the secondary aims were to assess the safety, anti-tumor activity, and the pharmacokinetics. 1, 2

Data from the trial demonstrated early signs of a potential therapeutic benefit in the dose-escalation stage. Of the 19 heavily pretreated patients with NHL, five patients achieved a complete response at doses of 0.6 – 4.2 mg/kg every 3 weeks. Tumor reductions were seen in patients with both indolent and aggressive disease. Patients with follicular, diffuse large cell, and mantle cell lymphoma maintained a durable response. TRPH-222 was well-tolerated with a benign safety profile. The trial is currently ongoing with dose level of 10 mg/kg every 3 weeks. 1, 2

  1. Pharma C. Triphase, Catalent announce interim TRPH-222 results in NHL. https://www.contractpharma.com/contents/view_breaking-news/2020-05-19/triphase-catalent-announce-interim-trph-222-results-in-nhl/. Published May 19, 2020. Accessed May 20, 2020.
  2. Garcia D. Interim results of phase I study confirms safety with early signs of efficacy for TRPH-222 in NHL - Onco'Zinehttps://www.oncozine.com/interim-results-of-phase-i-study-confirms-safety-with-early-signs-of-efficacy-for-trph-222-in-nhl/. Published May 18, 2020. Accessed May 20, 2020.

Share: